Categories: DNANews

CellarisBio Announces “CHALLENGING TARGET AWARD” to Promote Innovation in Drug Discovery

SAN DIEGO, Dec. 16, 2024 /PRNewswire/ — CellarisBio breaks ground with an announcement of “Challenging Target Award” to foster innovation in the space of challenging therapeutic targets. The award is designed to de-risk & accelerate first-in-class and best-in-class drug discovery programs. It will provide the awardee with exclusive access to CellarisBio’s MICRO-TAG cell target engagement platform. The platform enables:

  • Drug discovery using DNA-Encoded Libraries (DELs),
  • Hit-to-lead optimization,
  • Real-time analysis for mechanism-of-action studies.

The award will launch on January 15th, 2025, at https://cellarisbio.com/award and the winner will be announced on April 15th, 2025.

Our mission is to expand the druggable proteome for discovery of precision therapeutics. We are particularly keen on challenging drug targets, proteins that have been known as undruggable. We tackle them within the native environment of the cell.” stated Elmar Nurmemmedov, cofounder and CEO at CellarisBio. “There are more than 9000 undiscovered therapies that are locked behind challenging drug targets. We pledge to work closely with ambitious biotechs to unlock life-saving therapies of the future.” Elmar added.

“In the recent years, we have witnessed an evolution of drug discovery technologies and therapeutic modalities. It is now becoming increasingly imperative to use live cells as filters to de-risk and accelerate therapeutic findings. Demonstration of direct drug target engagement within the cellular environment is indispensable for drug pharmacology. The “Challenging Target Award” is agnostic to the target family, disease area and how drug candidates were discovered.” said Ivan Babic, cofounder at CellarisBio.

Watch the official CellarisBio trailer here: Youtube

Award link: CellarisBio

About CellarisBio
CellarisBio is a techbio company, developing the next-gen cell target engagement technology, delivered as MICRO-TAG™ platform. Based at Biovista labs in San Diego, CellarisBio, the company capitalizes on several patents protecting the technology. CellarisBio has recently fostered multiple partnerships with companies around the world.

Contact:
hi@cellarisbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cellarisbio-announces-challenging-target-award-to-promote-innovation-in-drug-discovery-302332222.html

SOURCE CellarisBio

Staff

Recent Posts

In HelloNation, Immigration Attorney Maleeha Haq of Newark, CA, Explains How the Asylum Process Works for Immigrants

NEWARK, Calif., Feb. 3, 2026 /PRNewswire/ -- What steps must immigrants take to navigate the…

2 hours ago

Medexus Schedules Third Fiscal Quarter 2026 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP)…

8 hours ago

In HelloNation, Family Counseling Expert Scott Ostrowski of Geneva Outlines Employee and Employer Support Services for HelloNation

GENEVA, N.Y., Feb. 3, 2026 /PRNewswire/ -- What are Employee and Employer Support Services, and…

8 hours ago

In HelloNation, Dental Lab Specialist Jeffrey Tolksdorf of Clinton Township, MI, Details What Happens Inside a Dental Lab

CLINTON TOWNSHIP, Mich., Feb. 3, 2026 /PRNewswire/ -- What actually happens after your dentist takes…

8 hours ago

In HelloNation, Water Treatment Expert Jason McGee of Loretto Explains the Importance of Precision in Water Treatment Chemistry

LORETTO, Tenn., Feb. 3, 2026 /PRNewswire/ -- How does precision in chemical dosing affect the…

8 hours ago

GLOBO Language Solutions Elevates Leadership with Executive Promotions

PHILADELPHIA, Feb. 3, 2026 /PRNewswire/ -- GLOBO Language Solutions, the leading B2B provider of interpreting and…

8 hours ago